News | Endoscopes | April 02, 2018

Multicenter prospective study results show with inclusion of WATS3D, overall detection of Barrett’s esophagus increased 83 percent, detection of dysplasia increased 88 percent

April 2, 2018 — Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D) device increases the detection of both Barrett’s esophagus and esophageal dysplasia by more than 80 percent. Study results from the multicenter trial of more than 4,000 patients were published in the latest issue of United European Gastroenterology Journal and featured in the American Society for Gastrointestinal Endoscopy (ASGE)’s Scope Tech Talk video series.

Esophageal adenocarcinoma, one of the most fatal and fastest growing cancers in the U.S., can be prevented if detected at a precancerous stage. Gastroenterologists perform more than 5 million upper endoscopies each year on patients with chronic heartburn and Barrett's esophagus in an effort to find these precancerous cells before they can progress to cancer. A major problem with this strategy is that prior to the availability of WATS3D, endoscopists had to rely on taking small random forceps biopsies at 1-2 cm intervals to find these abnormal cells, leaving more than 96 percent of the endoscopically suspect area completely untested.

With the availability of WATS3D, doctors are able to rapidly collect a sample from a much larger surface area of the esophagus. By combining a larger sampling area with 3-D imaging and cytopathology, WATS3D has far reaching implications for protecting a patient’s health, according to CDx Diagnostics, the makers of the solution. If precancerous cells are present, they can now be easily detected and removed or destroyed before they become cancerous – essentially pre-empting esophageal cancer.

The multicenter prospective trial was conducted at 25 community-based gastrointestinal (GI) centers across the United States. In the study, 4,203 patients were tested for esophageal disease. The findings show that with the inclusion of WATS3D overall detection of Barrett’s increased by 83 percent, while the detection of dysplasia increased by 88 percent. The study concludes that the sampling error can be improved dramatically with use of this adjunctive technique.

“These data confirm findings from previous clinical trials showing that WATS3D biopsy significantly increases the detection rate of Barrett's Esophagus as well as precancerous changes in esophageal tissue in GERD patients," said Seth Gross, M.D., lead investigator. “Ultimately, WATS3D revolutionary technology is making esophageal cancer a potentially preventable disease.”

“This study exhibits the fundamental limitation with standard forceps biopsies in the setting of Barrett’s diagnosis and surveillance and sheds light on the 'sampling error' phenomenon that may provide false reassurance to both patients and GI professionals,” said Vivek Kaul, M.D., Segal-Watson Professor of Medicine and chief of the Division of Gastroenterology and Hepatology at the University of Rochester Medical Center. “These results clearly demonstrate that the wide-area sampling and expert analysis aspects of WATS3D technology can effectively help fill the information gap in diagnosis and surveillance for patients with Barrett’s esophagus.”

For more information: www.wats3d.com

 


Related Content

News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Population Health

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Time April 04, 2024
arrow
News | Radiology Business

April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc., GE HealthCare ...

Time April 02, 2024
arrow
News | Radiation Oncology

April 2, 2024 — In a 10-center study, microwave ablation offered progression free survival rates and fewer complications ...

Time April 02, 2024
arrow
News | ACR

March 21, 2024 — The Advanced Research Projects Agency for Health (ARPA-H) has appointed American College of Radiology ...

Time March 21, 2024
arrow
Subscribe Now